Cempra (CEMP) Posts Wider Q2 Loss

Cempra (NASDAQ: CEMP) reported Q2 EPS of ($0.57), $0.15 worse than the analyst estimate of ($0.42).

"Cempra's positive momentum continued in the second quarter and thereafter with the completion of patient enrollment in the Solitaire IV Phase 3 clinical trial in CABP representing a significant milestone for the company," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "We anticipate announcing top line results from this important study by the end of 2015. In addition, we look forward to initiating our planned Phase 2 studies investigating the potential use of solithromycin in chronic obstructive pulmonary disease (COPD) and in nonalcoholic steatohepatitis (NASH), which we expect to begin soon. Subject to positive results from our Solitaire IV trial, we believe we remain on track for an NDA filing for solithromycin in 2016 and our pre-commercialization readiness activities are continuing."

For earnings history and earnings-related data on Cempra (CEMP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c